MARYLIE BUCKOSKI: Open Payments
NPI 1649756586 · ARLINGTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,190 in 59 payments from 15 companies in 2025. Trend: 2023 $480 · 2024 $1,399 · 2025 $1,190
Food & beverage: $1,190
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 17 | $343 |
| AstraZeneca Pharmaceuticals LP | 11 | $227 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $150 |
| Insmed, Inc. | 5 | $105 |
| Verona Pharma, Inc. | 4 | $83 |
| Electromed, Inc. | 5 | $61 |
| GENZYME CORPORATION | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| United Therapeutics Corporation | 1 | $27 |
| Philips North America LLC | 1 | $23 |
Products named: NUCALA, FASENRA, Arikayce, DUPIXENT, Ohtuvayre, TRELEGY ELLIPTA, SMARTVEST, TEZSPIRE.
Industry payments across TX — which companies pay providers there.
